astmedАстраханский медицинский журналAstrakhan medical journal1992-6499ФГБОУ ВО Астраханский ГМУ Минздрава России10.17021/1992-6499-2025-1-6-15astmed-365Research ArticleНАУЧНЫЕ ОБЗОРЫSCIENTIFIC REVIEWSНеобходимость применения пробиотиков в схеме лечения пациентов с сердечно-сосудистыми заболеваниямиThe need for probiotics the using in the treatment of patients with cardiovascular diseaseshttps://orcid.org/0000-0001-9209-7839ЧервинецЮ. В.ChervinetsJ. V.

Юлия Вячеславовна Червинец, доктор медицинских наук, профессор, заведующий кафедрой микробиологии и вирусологии с курсом иммунологии

Тверь

Julija V. Chervinets, Dr. Sci. (Med.), Professor, Head of the Department

Tver

julia_chervinec@mail.ruhttps://orcid.org/0009-0003-5903-6702СтепановаЭ. В.StepanovaE. V.

Эмма Валерьевна Степанова, аспирант кафедры микробиологии и вирусологии с курсом иммунологии

Тверь

Emma V. Stepanova, postgraduate student

Tver

s-emma@list.ruhttps://orcid.org/0000-0001-6549-0010ЧервинецВ. М.ChervinetsV. M.

Вячеслав Михайлович Червинец, доктор медицинских наук, профессор кафедры микробиологии и вирусологии с курсомиммунологии

Тверь

Vyacheslav M. Chervinets, Dr. Sci. (Med.), Professor of the Department

Tver

chervinets@mail.ruhttps://orcid.org/0000-0002-7165-5077БеляевВ. С.BelyaevV. S.

Всеволод Станиславович Беляев, ассистент кафедры микробиологии и вирусологии с курсом иммунологии

Тверь

Vsevolod S. Belyaev, Assistant

Tver

seva.belyaev.99@mail.ruhttps://orcid.org/0009-0009-2617-3632ЩукинаА. О.SchukinaA. O.

Александра Олеговна Щукина, студентка 4 курса педиатрического факультета

Тверь

Aleksandra O. Schukina, student

Tver

aleksandra162002@mail.ruhttps://orcid.org/0009-0005-3610-560XПогосянА. С.PogosjanA. S.

Альберт Самвелович Погосян, студент 5 курса стоматологического факультета

Тверь

Al'bert S. Pogosjan, student

Tver

albert-pogosyan-2001@mail.ruТверской государственный медицинский университетРоссияTver State Medical UniversityRussian Federation202523042025201615Copyright © Червинец Ю.В., Степанова Э.В., Червинец В.М., Беляев В.С., Щукина А.О., Погосян А.С., 20252025Червинец Ю.В., Степанова Э.В., Червинец В.М., Беляев В.С., Щукина А.О., Погосян А.С.Chervinets J.V., Stepanova E.V., Chervinets V.M., Belyaev V.S., Schukina A.O., Pogosjan A.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.astmedj.ru/jour/article/view/365

В представленном обзоре литературы показана важность включения пробиотических препаратов в схему лечения пациентов с сердечно-сосудистыми заболеваниями. Проанализированы актуальные источники литературы с использованием баз данных PubMed, Science direct, Elibrary, Google scholar. Потенциальных механизмов воздействия пробиотиков на сердечно-сосудистую систему может быть много: синтез короткоцепочечных жирных кислот, уменьшение эндотоксинемии в крови, регуляция свертывающей системы крови, уменьшение синтеза триметил-N-оксид и т. д. Существует достаточное количество и экспериментальных, и клинических исследований, которые подтверждают эффективность применения пробиотических препаратов у пациентов с кардиальной патологией. Важной задачей врача-кардиолога является выбор пробиотического препарата, его клинически эффективной дозировки, продолжительности лечения и возможности сочетания с привычной кардиологической терапией.

This literature review shows the importance of including probiotic drugs in the treatment of patients with cardiovascular diseases. Current literature sources were analyzed using the PubMed, Science direct, Elibrary, and Google scholar databases. There are a lot of potential mechanisms of the probiotics effect on the cardiovascular system: synthesis of SCFAs, reduction of endotoxinemia in the blood, regulation of the blood coagulation system, reduction of TMAO synthesis, etc. There are many studies experimental (with laboratory animals) and clinical, that prove pathogenetically and clinically the effectiveness of the probiotic drugs using in patients with cardiac pathology. An important task for a cardiologist is the choice of a probiotic drug, its clinically effective dosage, duration of treatment, and the possibility of combination with conventional cardiac therapy

сердечно-сосудистые заболеванияпробиотикиось «кишечник – сердце»cardiovascular diseaseprobioticsgut-heart axisReferencesБойцов С. А., Драпкина О. М., Шляхто Е. В., Конради А. О., Баланова Ю. А., Жернакова Ю. В., Метельская В. А., Ощепкова Е. В., Ротарь О. П., Шальнова С. А. Исследование ЭССЕ-РФ (Эпидемиология сердечно-сосудистых заболеваний и их факторов риска в регионах Российской Федерации). Десять лет спустя // Кардиоваскулярная терапия и профилактика. 2021. Т. 20 (5). 3007. doi: 10.15829/1728-8800-2021-3007.Boytsov S. A., Drapkina O. M., Shlyakhto E. V., Konradi A. O., Balanova Yu. A., Zhernakova Yu. V., Metelskaya V. A., Oshchepkova E. V., Rotar O. P., Shalnova S. A. Study ESSE-R.F. (Epidemiology of cardiovascular diseases and their risk factors in the regions of the Russian Federation). Ten years later. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2021; 20 (5): 3007. doi: 10.15829/1728-8800-2021-3007 (In Russ.).Шальнова С. А., Драпкина О. М., Куценко В. А., Капустина А. В., Муромцева Г. А. Инфаркт миокарда в популяции некоторых регионов России и его прогностическое значение // Российский кардиологический журнал. 2022. Т. 27 (6). 4952. doi: 10.15829/1560-4071-2022-4952.Shalnova S. A., Drapkina O. M., Kutsenko V. A., Kapustina A. V., Muromtseva G. A. et al. Myocardial infarction in the population of some regions of Russia and its prognostic significance. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2022; 27 (6): 4952. https://doi.org/10.15829/1560-4071-2022-4952 (In Russ.).Oniszczuk A., Oniszczuk T., Gancarz M., Szymańska J. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases // Molecules. 2021. Vol. 26 (4). 1172. doi: 10.3390/molecules26041172. PMID: 33671813; PMCID: PMC7926819.Oniszczuk A., Oniszczuk T., Gancarz M., Szymańska J. Role of Gut Microbiota, Probiotics and Prebiotics in the Cardiovascular Diseases. Molecules. 2021; 26 (4): 1172. doi: 10.3390/molecules26041172. PMID: 33671813; PMCID: PMC7926819.Matsiras D., Bezati S., Ventoulis I., Verras C., Parissis J., Polyzogopoulou E. Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut-Heart Axis // Journal of Clinical Medicine. 2023.Vol. 12 (7). 2567. doi: 10.3390/jcm12072567. PMID: 37048650; PMCID: PMC10095379.Matsiras D., Bezati S., Ventoulis I., Verras C., Parissis J., Polyzogopoulou E. Gut Failure: A Review of the Pathophysiology and Therapeutic Potentials in the Gut-Heart Axis. Journal of Clinical Medicine. 2023; 12 (7): 2567. doi: 10.3390/jcm12072567. PMID: 37048650; PMCID: PMC10095379.Janeiro M. H., Ramírez M. J., Milagro F. I., Martínez J. A., Solas M. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target // Nutrients. 2018. Vol. 10 (10). 1398. doi: 10.3390/nu10101398.Janeiro M. H., Ramírez M. J., Milagro F. I., Martínez J. A., Solas M. Implication of Trimethylamine N-Oxide (TMAO) in Disease: Potential Biomarker or New Therapeutic Target. Nutrients. 2018; 10 (10): 1398. doi: 10.3390/nu10101398.Carmela Cosola, Maria Teresa Rocchetti, Adamasco Cupisti, Loreto Gesualdo. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease // Pharmacological Research. 2018. Vol. 130. P. 132–142.Carmela Cosola, Maria Teresa Rocchetti, Adamasco Cupisti, Loreto Gesualdo. Microbiota metabolites: Pivotal players of cardiovascular damage in chronic kidney disease. Pharmacological Research. 2018; 130: 132–142.Lässiger-Herfurth A., Pontarollo G., Grill A., Reinhardt C. The Gut Microbiota in Cardiovascular Disease and Arterial Thrombosis // Microorganisms. 2019. Vol. 7 (12). 691. doi: 10.3390/microorganisms7120691. PMID: 31847071; PMCID: PMC6956001.Lässiger-Herfurth A., Pontarollo G., Grill A., Reinhardt C. The Gut Microbiota in Cardiovascular Disease and Arterial Thrombosis. Microorganisms. 2019; 7 (12): 691. doi: 10.3390/microorganisms7120691. PMID: 31847071; PMCID: PMC6956001.Mohammad S., Thiemermann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions // Frontiers in Immunology. 2021 Jan 11; 11:594150. doi: 10.3389/fimmu.2020.594150. PMID: 33505393; PMCID: PMC7829348.Mohammad S., Thiemermann C. Role of Metabolic Endotoxemia in Systemic Inflammation and Potential Interventions. Frontiers in Immunology. 2021; 11: 594150. doi: 10.3389/fimmu.2020.594150. PMID: 33505393; PMCID: PMC7829348.Violi F., Cammisotto V., Bartimoccia S., Pignatelli P., Carnevale R., Nocella C. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease // Nature Reviews Cardiology. 2023. Vol. 20 (1). P. 24–37. doi: 10.1038/s41569-022-00737-2. PMID: 35840742; PMCID: PMC9284488.Violi F., Cammisotto V., Bartimoccia S., Pignatelli P., Carnevale R., Nocella C. Gut-derived low-grade endotoxaemia, atherothrombosis and cardiovascular disease. Nature Reviews Cardiology. 2023; 20 (1): 24–37. doi: 10.1038/s41569-022-00737-2. Epub 2022 Jul 15. PMID: 35840742; PMCID: PMC9284488.Mawhin M. A., Tilly P., Zirka G., Charles A. L., Slimani F., Vonesch J. L., Michel J. B., Bäck M., Norel X., Fabre J. E. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia // Cardiovascular Research. 2018. Vol. 114 (12). P. 1656–1666. doi: 10.1093/cvr/cvy130. PMID: 29800147.Mawhin M. A., Tilly P., Zirka G., Charles A. L., Slimani F., Vonesch J. L., Michel J. B., Bäck M., Norel X., Fabre J. E. Neutrophils recruited by leukotriene B4 induce features of plaque destabilization during endotoxaemia. Cardiovascular Research. 2018; 114 (12): 1656–1666. doi: 10.1093/cvr/cvy130. PMID: 29800147.Khan M. J., Gerasimidis K., Edwards C. A., Shaikh M. G. Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature // Journal of Obesity. 2016; 2016: 7353642. doi: 10.1155/2016/7353642.Khan M. J., Gerasimidis K., Edwards C. A., Shaikh M. G. Role of Gut Microbiota in the Aetiology of Obesity: Proposed Mechanisms and Review of the Literature. Journal of Obesity. 2016; 2016: 7353642. doi: 10.1155/2016/7353642.Kim J., Yang G., Kim Y., Kim J., Ha J. AMPK activators: mechanisms of action and physiological activities // Experimental & Molecular Medicine. 2016. Vol. 48 (4). e224. doi: 10.1038/emm.2016.16.Kim J., Yang G., Kim Y., Kim J., Ha J. AMPK activators: mechanisms of action and physiological activities. Experimental & Molecular Medicine. 2016; 48 (4): e224. doi: 10.1038/emm.2016.16.Natarajan N., Hori D., Flavahan S. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41 // Physiological Genomics. 2016. Vol. 48 (11). P. 826–834. doi: 10.1152/physiolgenomics.00089.2016.Natarajan N., Hori D., Flavahan S. Microbial short chain fatty acid metabolites lower blood pressure via endothelial G protein-coupled receptor 41. Physiological Genomics. 2016; 48 (11): 826–834. doi: 10.1152/physiolgenomics.00089.2016.Yu H., Qin L., Hu H., Wang Z. Alteration of the Gut Microbiota and Its Effect on AMPK/NADPH Oxidase Signaling Pathway in 2K1C Rats // BioMed Research International. 2019. Vol. 2019. 8250619. doi: 10.1155/2019/8250619.Yu H., Qin L., Hu H., Wang Z. Alteration of the Gut Microbiota and Its Effect on AMPK/NADPH Oxidase Signaling Pathway in 2K1C Rats. BioMed Research International. 2019; 2019: 8250619. doi: 10.1155/2019/8250619.Kamo T., Akazawa H., Suda W., Saga-Kamo A., Shimizu Y. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure // PLoS One. 2017. Vol. 12 (3). e0174099. https://doi.org/10.1371/journal.pone.0174099.Kamo T., Akazawa H., Suda W., Saga-Kamo A., Shimizu Y. Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS One. 2017; 12 (3): e0174099. https://doi.org/10.1371/journal.pone.0174099.Sun W., Du D., Fu T., Han Y., Li P., Ju H. Alterations of the Gut Microbiota in Patients With Severe Chronic Heart Failure // Frontiers in Microbiology. 2022. Vol. 12. 813289. doi: 10.3389/fmicb.2021.813289. PMID: 35173696; PMCID: PMC8843083.Sun W., Du D., Fu T., Han Y., Li P., Ju H. Alterations of the Gut Microbiota in Patients With Severe Chronic Heart Failure. Frontiers in Microbiology. 2022; 12: 813289. doi: 10.3389/fmicb.2021.813289. PMID: 35173696; PMCID: PMC8843083.Han Y., Gong Z., Sun G., Xu J., Qi C., Sun W., Jiang H., Cao P., Ju H. Dysbiosis of Gut Microbiota in Patients With Acute Myocardial Infarction // Frontiers in Microbiology. 2021. Vol. 12. 680101. doi: 10.3389/fmicb.2021.680101. PMID: 34295318; PMCID: PMC8290895 5.Han Y., Gong Z., Sun G., Xu J., Qi C., Sun W., Jiang H., Cao P., Ju H. Dysbiosis of Gut Microbiota in Patients With Acute Myocardial Infarction. Frontiers in Microbiology. 2021; 12: 680101. doi: 10.3389/fmicb.2021.680101. PMID: 34295318; PMCID: PMC8290895 5.Sadeghzadeh J., Vakili A., Sameni H. R., Shadnoush M., Bandegi A. R., Zahedi Khorasani M. The Effect of Oral Consumption of Probiotics in Prevention of Heart Injury in a Rat Myocardial Infarction Model: a Histopathological, Hemodynamic and Biochemical Evaluation // Iran Biomedical Journal. 2017. Vol. 21 (3). P. 174–181. doi: 10.18869/acadpub.ibj.21.3.174. PMID: 27874107; PMCID: PMC5392220.Sadeghzadeh J., Vakili A., Sameni H. R., Shadnoush M., Bandegi A. R., Zahedi Khorasani M. The Effect of Oral Consumption of Probiotics in Prevention of Heart Injury in a Rat Myocardial Infarction Model: a Histopathological, Hemodynamic and Biochemical Evaluation. Iran Biomedical Journal. 2017; 21 (3): 174–181. doi: 10.18869/acadpub.ibj.21.3.174. PMID: 27874107; PMCID: PMC5392220.Borshchev Y. Y., Sonin D. L., Burovenko I. Y., Borshchev V. Y., Cheburkin Y. V., Borshcheva O. V., Galagudza M. M. The Effect of Probiotic Strains on Myocardial Infarction Size, Biochemical and Immunological Parameters in Rats with Systemic Inflammatory Response Syndrome and Polymorbidity // Journal of Evolutionary Biochemistry and Physiology. 2022. Vol. 58 (6). P. 2058–2069. doi: 10.1134/S0022093022060321. PMID: 36573161; PMCID: PMC9773675.Borshchev Y. Y., Sonin D. L., Burovenko I. Y., Borshchev V. Y., Cheburkin Y. V., Borshcheva O. V., Galagudza M. M. The Effect of Probiotic Strains on Myocardial Infarction Size, Biochemical and Immunological Parameters in Rats with Systemic Inflammatory Response Syndrome and Polymorbidity. Journal of Evolutionary Biochemistry and Physiology. 2022; 58 (6): 2058–2069. doi: 10.1134/S0022093022060321. PMID: 36573161; PMCID: PMC9773675.Gan X. T., Ettinger G., Huang C. X., Burton J. P., Haist J. V., Rajapurohitam V., Sidaway J. E., Martin G., Gloor G. B., Swann J. R., Reid G., Karmazyn M. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat // Circulation Heart Failure. 2014. Vol. 7 (3). P. 491–499. doi: 10.1161/CIRCHEARTFAILURE.113.000978. PMID: 2462536.Gan X. T., Ettinger G., Huang C. X., Burton J. P., Haist J. V., Rajapurohitam V., Sidaway J. E., Martin G., Gloor G. B., Swann J. R., Reid G., Karmazyn M. Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circulation Heart Failure. 2014; 7 (3): 491–499. doi: 10.1161/CIRCHEARTFAILURE.113.000978. PMID: 2462536.Wang J., Chen J., Li L., Zhang H., Pang D., Ouyang H., Jin X., Tang X. Clostridium butyricum and Bifidobacterium pseudolongum Attenuate the Development of Cardiac Fibrosis in Mice // Microbiology Spectrum. 2022. Vol. 10 (6). e0252422. doi: 10.1128/spectrum.02524-22. PMID: 36318049; PMCID: PMC9769846.Wang J., Chen J., Li L., Zhang H., Pang D., Ouyang H., Jin X., Tang X. Clostridium butyricum and Bifidobacterium pseudolongum Attenuate the Development of Cardiac Fibrosis in Mice. Microbiology Spectrum. 2022; 10 (6): e0252422. doi: 10.1128/spectrum.02524-22. PMID: 36318049; PMCID: PMC9769846.Sun B., Ma T., Li Y., Yang N., Li B., Zhou X., Guo S., Zhang S., Kwok L. Y., Sun Z., Zhang H. Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes // mSystems. 2022. Vol. 7 (2). e0010022. doi: 10.1128/msystems.00100-22. PMID: 35343796; PMCID: PMC9040731.Sun B., Ma T., Li Y., Yang N., Li B., Zhou X., Guo S., Zhang S., Kwok L. Y., Sun Z., Zhang H. Bifidobacterium lactis Probio-M8 Adjuvant Treatment Confers Added Benefits to Patients with Coronary Artery Disease via Target Modulation of the Gut-Heart/-Brain Axes. mSystems. 2022; 7 (2): e0010022. doi: 10.1128/msystems.00100- 22. PMID: 35343796; PMCID: PMC9040731.Meng H., Ba Z., Lee Y., Peng J., Lin J., Fleming J. A., Furumoto E. J., Roberts R. F., Kris-Etherton P. M., Rogers C. J. Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults // European Journal of Nutrition. 2017. Vol. 56 (2). P. 649–661. doi: 10.1007/s00394-015-1109-5. PMID: 26621631.Meng H., Ba Z., Lee Y., Peng J., Lin J., Fleming J. A., Furumoto E. J., Roberts R. F., Kris-Etherton P. M., Rogers C. J. Consumption of Bifidobacterium animalis subsp. lactis BB-12 in yogurt reduced expression of TLR-2 on peripheral blood-derived monocytes and pro-inflammatory cytokine secretion in young adults. European Journal of Nutrition. 2017; 56 (2): 649–661. doi: 10.1007/s00394-015-1109-5. PMID: 26621631.Moludi J., Kafil H. S., Qaisar S. A., Gholizadeh P., Alizadeh M., Vayghyan H. J. Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial // Journal of Nutrition. 2021. Vol. 20 (1). P. 47. doi: 10.1186/s12937-021-00703-7. PMID: 34074289; PMCID: PMC8170788.Moludi J., Kafil H. S., Qaisar S. A., Gholizadeh P., Alizadeh M., Vayghyan H. J. Effect of probiotic supplementation along with calorie restriction on metabolic endotoxemia, and inflammation markers in coronary artery disease patients: a double blind placebo controlled randomized clinical trial. Journal of Nutrition. 2021; 20 (1): 47. doi: 10.1186/s12937-021-00703-7. PMID: 34074289; PMCID: PMC8170788.Sabico S., Al-Mashharawi A., Al-Daghri N. M., Wani K., Amer O. E., Hussain D. S., Ahmed Ansari M. G., Masoud M. S., Alokail M. S., McTernan P. G. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo-controlled trial // Clinical Nutrition. 2019. Vol. 38 (4). P. 1561–1569. doi: 10.1016/j.clnu.2018.08.009. PMID: 30170781.Sabico S., Al-Mashharawi A., Al-Daghri N. M., Wani K., Amer O. E., Hussain D. S., Ahmed Ansari M. G., Masoud M. S., Alokail M. S., McTernan P. G. Effects of a 6-month multi-strain probiotics supplementation in endotoxemic, inflammatory and cardiometabolic status of T2DM patients: A randomized, double-blind, placebo- controlled trial. Clinical Nutrition. 2019; 38 (4): 1561–1569. doi: 10.1016/j.clnu.2018.08.009. PMID: 30170781.Malik M., Suboc T. M., Tyagi S., Salzman N., Wang J., Ying R., Tanner M. J., Kakarla M., Baker J. E., Widlansky M. E. Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease // Circulation Research. 2018. Vol. 123 (9). P. 1091–1102. doi: 10.1161/CIRCRESAHA.118.313565. PMID: 30355158; PMCID: PMC6205737.Malik M., Suboc T. M., Tyagi S., Salzman N., Wang J., Ying R., Tanner M. J., Kakarla M., Baker J. E., Widlansky M. E. Lactobacillus plantarum 299v Supplementation Improves Vascular Endothelial Function and Reduces Inflammatory Biomarkers in Men With Stable Coronary Artery Disease. Circulation Research. 2018; 123 (9): 1091–1102. doi: 10.1161/CIRCRESAHA.118.313565. PMID: 30355158; PMCID: PMC6205737.Trotter R. E., Vazquez A. R., Grubb D. S., Freedman K. E., Grabos L. E., Jones S., Gentile C. L., Melby C. L., Johnson S. A., Weir T. L. Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults // Beneficial Microbes. 2020. Vol. 11 (7). P. 621–630. doi: 10.3920/BM2020.0039. PMID: 33161737; PMCID: PMC8773468.Trotter R. E., Vazquez A. R., Grubb D. S., Freedman K. E., Grabos L. E., Jones S., Gentile C. L., Melby C. L., Johnson S. A., Weir T. L. Bacillus subtilis DE111 intake may improve blood lipids and endothelial function in healthy adults. Beneficial Microbes. 2020; 11 (7): 621–630. doi: 10.3920/BM2020.0039. PMID: 33161737; PMCID: PMC8773468.Khongrum J., Yingthongchai P., Boonyapranai K., Wongtanasarasin W., Aobchecy P., Tateing S., Prachansuwan A., Sitdhipol J., Niwasabutra K., Thaveethaptaikul P., Phapugrangkul P., Chonpathompikunlert P. Safety and Effects of Lactobacillus paracasei TISTR 2593 Supplementation on Improving Cholesterol Metabolism and Atherosclerosis-Related Parameters in Subjects with Hypercholesterolemia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial // Nutrients. 2023. Vol. 15 (3). P. 661. doi: 10.3390/nu15030661. PMID: 36771367; PMCID: PMC9921995.Khongrum J., Yingthongchai P., Boonyapranai K., Wongtanasarasin W., Aobchecy P., Tateing S., Prachansuwan A., Sitdhipol J., Niwasabutra K., Thaveethaptaikul P., Phapugrangkul P., Chonpathompikunlert P. Safety and Effects of Lactobacillus paracasei TISTR 2593 Supplementation on Improving Cholesterol Metabolism and Atherosclerosis-Related Parameters in Subjects with Hypercholesterolemia: A Randomized, Double-Blind, Placebo- Controlled Clinical Trial. Nutrients. 2023; 15 (3): 661. doi: 10.3390/nu15030661. PMID: 36771367; PMCID: PMC9921995.Costabile A., Buttarazzi I., Kolida S., Quercia S., Baldini J., Swann J. R., Brigidi P., Gibson G. R. An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults // PLoS One. 2017. Vol. 12 (12). e0187964. doi: 10.1371/journal.pone.0187964. PMID: 29228000; PMCID: PMC5724841.Costabile A., Buttarazzi I., Kolida S., Quercia S., Baldini J., Swann J. R., Brigidi P., Gibson G. R. An in vivo assessment of the cholesterol-lowering efficacy of Lactobacillus plantarum ECGC 13110402 in normal to mildly hypercholesterolaemic adults. PLoS One. 2017; 12 (12): e0187964. doi: 10.1371/journal.pone.0187964. PMID: 29228000; PMCID: PMC5724841.Szulińska M., Łoniewski I., Skrypnik K., Sobieska M., Korybalska K., Suliburska J., Bogdański P. Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study // Nutrients. 2018. Vol. 10 (11). P. 1672. doi: 10.3390/nu10111672. PMID: 30400570; PMCID: PMC6265939.Szulińska M., Łoniewski I., Skrypnik K., Sobieska M., Korybalska K., Suliburska J., Bogdański P. Multispecies Probiotic Supplementation Favorably Affects Vascular Function and Reduces Arterial Stiffness in Obese Postmenopausal Women-A 12-Week Placebo-Controlled and Randomized Clinical Study. Nutrients. 2018; 10 (11): 1672. doi: 10.3390/nu10111672. PMID: 30400570; PMCID: PMC6265939.

The authors declare that there are no conflicts of interest present.